Contrive Datum Insights has published "Urokinase For Injection Market Size, Share & Industry Analysis, By Type (Urokinase Powder, Urokinase Solution), Application (Hospital, Clinic), Indication (Pulmonary Embolism, Acute Myocardial Infarction, Catheter Occlusion Management, Peripheral Arterial Thrombosis), Dosage strength (250,000 IU, 500,000 IU, 1,000,000 IU), Route of administration (Intravenous Administration, Catheter-Directed Administration), and Regional Forecast, 2026-2034". The study sizes the global urokinase for injection market at USD 295 million in 2025 and projects growth from USD 312 million in 2026 to USD 482 million by 2034, a compound annual growth rate of 5.59% across the forecast period.
Urokinase for injection is a thrombolytic enzyme, derived from human cell cultures or recombinant sources, formulated as a lyophilized powder or ready-to-use solution for intravenous or catheter-directed administration. It is used in hospital and outpatient interventional settings to dissolve blood clots in conditions such as pulmonary embolism, occluded catheters and peripheral arterial thrombosis. Buyers are hospital pharmacies, interventional radiology and vascular surgery departments, and dialysis centers that stock the drug for emergency and scheduled thrombolytic procedures.
Rising incidence of venous thromboembolism and expanding catheter-directed thrombolysis
Rising incidence of venous thromboembolism and expanding catheter-directed thrombolysis is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 5.59% a year, the type lines exposed to it move fastest: Urokinase Solution compounds at 7.23%, taking its share of revenue from 32% to 36.99% and its value from USD 94.4 million to USD 178.3 million.
A more favourable outcome is possible. If faster clinical adoption of catheter-directed thrombolysis alongside accelerated hospital and interventional radiology capacity expansion across Asia Pacific and Latin America, with no material new safety or supply disruption, 2034 revenue reaches USD 553 million instead of the USD 482 million the base case carries.
Set against the drivers, substitution by recombinant tissue plasminogen activator and newer anticoagulants in developed markets limits the pace. 68% of 2025 revenue sits in Urokinase Powder at 4.72% growth, below the market's 5.59%.
Where the Competition Actually Sits
The type axis, not the regional one, is what divides the field. Urokinase Powder is the volume position, 68% of 2025 revenue at USD 200.6 million, holding 63.01% through 2034, and it is defended by scale. Urokinase Solution is the growth position at 7.23%, and it is open. Strength in one does not carry into the other.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Application | Hospital | 78% · USD 230.1 million | Clinic 7.58% |
| Indication | Pulmonary Embolism | 38% · USD 112.1 million | Catheter Occlusion Management 6.67% |
| Dosage strength | 500,000 IU | 45% · USD 132.8 million | 1,000,000 IU 7.78% |
| Route of administration | Intravenous Administration | 70% · USD 206.5 million | Catheter-Directed Administration 8.42% |
- Based on regional analysis, Asia Pacific led the global urokinase for injection market in 2025 with 42% of global revenue at USD 123.9 million, reaching USD 216.9 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 42% in 2025 to 45% in 2034, with revenue growing from USD 123.9 million to USD 216.9 million.
- At 7% of 2025 revenue and 8% by 2034, Middle East and Africa is the smallest region throughout.
- Urokinase Powder was the leading type line in 2025, taking 68% of revenue at USD 200.6 million.
- Urokinase Solution is projected to grow at 7.23% over the forecast period, the fastest of any type line.
- China is the largest single country market at USD 55.8 million in 2025, 18.92% of global revenue.
Coverage runs to five axes, by type, and by application, indication, dosage strength and route of administration, with a revenue figure and a growth rate for every line in every year from 2020 to 2034, and bear, base and bull cases on the headline total at USD 417 million and USD 553 million by 2034. All five regions are broken out to country level, alongside the competitive landscape and the methodology behind each estimate. The study is delivered as a PDF, and a free sample can be requested.